The AI medical search engine OpenEvidence is reportedly valued at $15 billion after a $250 million round, according to reports from late September 2026 that relied on unnamed sources and that we could not match to a company confirmation. The company’s product is a free, AI-powered search tool for physicians that links answers to sources, according to the reports. This industry report looks at the business behind the AI medical search engine: how it is reported to make money, what the usage and revenue figures mean, why acquirers might be interested and what buyers and partners should ask. It is not investment advice.
AI medical search engine: key takeaways
- Reported, not confirmed: $250 million at a $15 billion valuation, from $12 billion in January 2026.
- The product is free for physicians and is reported to earn revenue from advertising aimed at medical professionals and other commercial relationships.
- Usage is company-stated: more than 40% of US physicians and about 18 million consultations in December 2025, according to one report.
- Revenue estimates differ: over $100 million annualised by January 2026 in one report, and about $300 million by mid-2026 in a third-party estimate.
- Acquisition interest is reported and unconfirmed.
How the AI medical search engine reportedly makes money
The reports say clinicians do not pay for the service. Revenue is reported to come from advertising aimed at medical professionals and from other commercial relationships. In this model the physician audience is the asset, and pharmaceutical and device marketers are among the natural buyers of access. The company website, OpenEvidence, describes the product for clinicians, and we did not find a public description of its advertising rules in what we reviewed.
Advertising inside clinical tools: general background
General background: when a free clinical tool is paid for by advertising, the central questions are separation and disclosure. Readers generally expect sponsored content to be clearly labelled, kept out of the evidence summary and not to change which sources an answer cites. Medical journals, conference organisers and drug-information services have long used similar rules. How the company applies them has not been described in the reports we reviewed, so buyers and partners are likely to ask for it directly.
Reading the numbers behind the AI medical search engine
This section is our calculation. If the third-party estimate of about $300 million in annualised revenue is right, the reported $15 billion valuation is about 50 times revenue. If the lower figure of $100 million reported for January is used, the multiple is far higher, though the dates differ and revenue has probably grown. Neither revenue number is audited or confirmed by the company in the material we saw, and a valuation at this multiple is a bet on continued growth and on the strength of the physician audience.
The funding trail of the AI medical search engine
One report puts the valuation at roughly $6 billion in October 2025, and a $250 million round at $12 billion followed in January 2026. The reported $15 billion would add 25% to the January figure. An earlier July report spoke of a possible raise at a higher valuation of $20 billion, and we could not reconcile it with the $15 billion now reported. One report names Andreessen Horowitz as lead investor, with hospital systems taking part, but we found this in a single source.
Why acquirers might be interested
This section is our analysis. A tool used by a large share of US physicians has data on what clinicians ask, a direct channel to them and growing links with health systems. One report says Memorial Sloan Kettering Cancer Center announced in September that it will integrate the product into Epic-based workflows and add an oncology knowledge base. Reports say large technology companies may have shown interest, and no offer has been disclosed. Buyers would also weigh the cost of keeping answers accurate and the risk attached to clinical content.
What hospital integration changes
This section is our analysis. A search tool inside the electronic health record is used at the point of care, which makes it more valuable and also raises the stakes. Hospital buyers would want to know who is responsible if a wrong answer influences a decision, how the tool is validated locally, how patient data is kept separate from the search service and how the tool is updated when guidance changes. These are procurement questions and not findings, and the reports we reviewed do not describe any such terms.
What buyers and partners should ask
- Is there independent testing of answer accuracy, and are the results published?
- How are advertising and clinical answers kept apart?
- Which data from physician use is retained, and how is it protected?
- Does the product fall under rules for clinical decision support software? See the FDA guidance on clinical decision support software.
- What does integration into a hospital record system change in liability and workflow?
The competitive context
General background: physician-facing AI search is a crowded area, with large technology firms, specialist start-ups and publishers all building tools for clinical questions, and health systems are also experimenting with in-house products. Earlier reports described OpenEvidence launching a free medical AI offering with a partner for doctors in many countries. A reported valuation tells investors something about the perceived value of physician reach, but it does not settle who will win. We do not rank competitors here.
What is not disclosed about the AI medical search engine
- Company confirmation of the round and the valuation.
- Audited revenue and the share from advertising.
- Independent accuracy testing of the answers.
- The identity and terms of any acquirer.
Risks and caveats on the AI medical search engine story
- Funding and sale reports rely on unnamed sources.
- Usage and revenue numbers differ by source and date.
- Advertising-supported clinical tools raise independence questions that the reports do not answer.
- This is news reporting, not investment advice.
In our assessment, the AI medical search engine race is being priced on physician reach, and the next real test is whether independent evidence of accuracy and a clear advertising policy keep that reach once scrutiny rises. The WHO guidance on the ethics and governance of artificial intelligence for health offers principles useful for judging such claims. More in our healthcare IT coverage.
What to watch next on the AI medical search engine
- Company confirmation or denial of the round and sale talk.
- Publication of independent accuracy testing.
- New health-system integrations and partnerships.
Frequently asked questions
What is an AI medical search engine?
A tool that answers clinical questions by searching medical literature and guidelines and summarising the results, ideally with links to sources.
How does OpenEvidence make money?
The reports say it is free to physicians and earns revenue from advertising aimed at medical professionals and other commercial relationships.
Is the $15 billion valuation confirmed?
Not in the material we reviewed. It comes from reports based on unnamed sources.
How we reported this: we relied on published reports from September 2026, the company website and public guidance from regulators and the WHO. General background, calculations and analysis are labelled. Last updated: 22 October 2026. This article is news reporting and not investment advice.
